Medtide Adopts Updated Articles of Association Defining Capital Structure and Governance Framework

Bulletin Express11-18 18:01

Medtide Inc. confirmed at its 18 June 2026 annual general meeting that shareholders have approved a comprehensive revision of the company’s Articles of Association. The document, effective immediately, consolidates the legal and governance framework that will steer the Hong Kong-listed peptide and oligonucleotide specialist through its next growth phase.

Key corporate profile • Legal form: Joint-stock limited company incorporated in the PRC in 2020. • Registered capital: RMB 141.80 million. • Share class: 141.80 million ordinary shares, all designated as H shares and listed on The Stock Exchange of Hong Kong since 30 June 2025. • Authorised future issuance: Up to 48.17 million additional H shares, subject to CSRC filing and HKEX approval.

Shareholder structure at establishment The Articles detail 12 founding shareholders, led by Health Angel International Limited (47.65 %), Hangzhou Haiding Technology (12.33 %) and Li Xiangli (8.22 %). All founders converted existing net assets into equity.

Capital management • Share buy-backs are permissible for seven clearly defined purposes, including employee incentives and convertible bond conversions; overall treasury holdings may not exceed 10 % of issued share capital and must be cancelled or re-allotted within statutory timeframes. • Financial assistance for share acquisitions is capped at 10 % of issued capital and requires shareholder approval. • Registered capital reductions or merger/division plans trigger mandatory creditor notifications and public announcements.

Lock-up and insider rules • Pre-IPO shares are restricted from transfer for 12 months post-listing. • Directors and senior management are limited to selling no more than 25 % of their holdings in any 12-month period during tenure and face a six-month lock-up after departure. • Short-swing profits realised within six months of purchase or sale by 5 %-plus holders must be returned to the company.

Governance architecture • Board composition: five to nine directors; independent non-executive directors (INEDs) must represent at least one-third of the board, with a minimum of three INEDs and at least one possessing accounting or financial expertise. • Term: three years, renewable by shareholder vote. • Board committees: Audit, Nomination and Remuneration Committees established; the Audit Committee assumes functions comparable to a supervisory board under PRC Company Law. • Senior management roles include Chief Executive Officer (General Manager), Chief Financial Officer and Board Secretary, all appointed by the board.

Shareholder rights and meetings • Annual general meeting (AGM) to be held within six months of each fiscal year-end; extraordinary meetings must be convened within two months when triggered by specified events. • Shareholders holding at least 1 % of issued shares can submit proposals; those with 10 % may requisition meetings. • Connected shareholders must abstain from voting on related-party transactions, and minority shareholder votes are counted separately on material matters. • Profit distribution: dividends (cash or scrip) to be paid within two months of approval, adhering to a “same share, same rights” principle.

Financial reporting and audit • Annual financial statements prepared within four months of year-end; quarterly reports within two months. • An external audit firm is engaged for a one-year renewable term, with appointment and remuneration subject to shareholder approval. • Internal audit function reports directly to the board.

Dissolution and liquidation The Articles outline dissolution triggers—including expiry of corporate term, shareholder resolution, regulatory action, or court order—and establish detailed liquidation procedures, creditor protections and liability provisions for directors and officers.

With the revised Articles in force, Medtide delineates clear operational, governance and shareholder-protection mechanisms, aligning its corporate constitution with PRC Company Law, the Securities Law and Hong Kong Listing Rules.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment